Zilovertamab vedotin

Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl auristatin E (MMAE). Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl auristatin E release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer. This product is for research use only.

Product Details
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Zilovertamab (anti-ROR1)
ADC cytotoxin (drug)	MMAE
Immunogen	Human ROR1
DAR (Drug to Antibody Ratio)	N/A
Purity	99%
Molecular Weight	145KDa
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	1xPBS